Frontlight ResearchEarly access
CompletedPhase 3
Open Label Study in Adolescents and Children With Myotonic Disorders
Key facts
- Who runs it
- Lupin Ltd.
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 12 people enrolled
- Started
- 3 Sept 2021
- Ended
- 8 Aug 2024
- Type of study
- Interventional
- Treatments tested
- Mexiletine
- Record updated
- 25 November 2024
Who can take part
- Age
- 6 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Male or female patients aged ≥ 6 and < 18 years who are able to comply with the study requirements
- A genetically confirmed diagnosis of NDM or DM (DM1or DM2)
- Presence of clinical symptoms of myotonia (hand grip myotonia, myotonia in the leg muscles, any other myotonia symptoms)
- No significant cardiac abnormalities as determined by a cardiologist's assessment of the ECG and echocardiogram performed within 3 months prior to enrolment in the study. (If not done within 3 months before trial, electrocardiogram (ECG) and echocardiogram assessments will be performed at screening)
- No history of any significant liver disorder
- Patients receiving mexiletine treatment agree to stop treatment at least 7 days prior to initiation of treatment with Namuscla
- Patients receiving other antimyotonic treatment agree to stop treatment for at least 7 times the half-life of respective drug
- Laboratory investigations for haematology, biochemistry, and urinalysis at screening are within the normal range, or showing no clinically relevant abnormal values, as judged by the Investigator
- Female patients of childbearing potential must be using an acceptable form of birth control as determined by the Investigator (e.g., oral contraception, implantable, injectable/transdermal hormonal contraception, intrauterine device (IUD), barrier methods), tubal ligation or are practicing abstinence
- Patients able to provide assent to study participation and a parent or legal guardian to sign the written informed consent prior to study entry
Who cannot take part
- Strong inducer or inhibitor of CYP2D6 or CYP1A2 within 7 days prior to study drug administration
- Any concurrent illness, or medications which could affect the muscle function
- Concurrent participation in any other clinical trial
- Any other neurological or psychiatric condition that might affect the study assessments
- Seizure disorder, diabetes mellitus requiring treatment by insulin
- Any contra-indication to mexiletine as listed in the Namuscla Summary of Product Characteristics (SmPC):; Hypersensitivity to the active substance, or to any of the excipients; Hypersensitivity to any local anaesthetic; Ventricular tachyarrhythmia; Complete heart block (i.e., third-degree atrioventricular block) or any heart block susceptible to evolve to complete heart block (first-degree atrioventricular block with markedly prolonged PR interval (≥ 200 ms) and/or wide QRS complex (≥ 120 ms), second-degree atrioventricular block, bundle branch block, bifascicular and trifascicular block),; QT interval > 450ms; Myocardial infarction (acute or past), or abnormal Q-waves; Symptomatic coronary artery disease; Heart failure with ejection fraction <50%; Atrial tachyarrhythmia, fibrillation or flutter; Sinus node dysfunction (including sinus rate < 50 bpm); Co-administration with medicinal products inducing torsades de pointes (class Ia, Ic, III antiarrhythmics): Co-administration of mexiletine and antiarrhythmics inducing torsades de pointesclass Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant) increases the risk of potentially lethal torsades de pointes; Co-administration with medicinal products with narrow therapeutic index
- Any clinically significant illness, laboratory findings, ECG, or other clinical symptoms, which in the opinion of the Investigator could affect the patient's optimal participation in the study
- Pregnant or breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an open-label, multi-centre, single arm, interventional study to describe the steady-state PK, safety, and efficacy of mexiletine in paediatric patients (6 to <18 years of age) with myotonic disorders.
The group in the trial
- Cohort 1 and 2Other group
7 patients aged 12 to \< 18 years , inclusive in cohort-1 7 patients aged 6 to \< 12 years, inclusive in cohort-2
Treatment: Mexiletine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-label, Non-Comparative Study to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of Mexiletine in Adolescents and Children With Myotonic Disorders
- Record updated
- 25 November 2024